In silico characterization of the interaction of AKR1B1 with the deacetylase activation domain (DAD)

Francisco J Gómez-Zaldívar1,2, Luis Córdova-Bahena1,3, Angel J Ruiz-Moreno1

  • 1School of Medicine, Universidad Nacional Autónoma de México (UNAM), Mexico City, Mexico.

Insights

Aldo-keto reductase family 1 member B1 (AKR1B1) interacts with SMRT

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cancer Research

Background:

  • Aldo-keto reductase family 1 member B1 (AKR1B1) is implicated in cancer progression.
  • AKR1B1 competes with histone deacetylase 3 for binding to the deacetylase activation domain (DAD) of SMRT.
  • The L289A mutation in AKR1B1 affects its dimerization with DAD, but the interaction details are unclear.

Purpose of the Study:

  • To model the DAD/AKR1B1 dimer using molecular docking.
  • To characterize the DAD/AKR1B1 complex stability and interactions via molecular dynamics simulations.
  • To identify key residues mediating the DAD/AKR1B1 interface through in silico mutagenesis.

Main Methods:

  • Molecular docking to model the DAD/AKR1B1 dimer.
  • Molecular dynamics simulations to analyze complex stability and structural dynamics.
  • In silico mutagenesis to assess residue contributions to the interface.

Main Results:

  • A novel, more stable DAD/AKR1B1 dimer model was identified.
  • The new model showed reduced disruption of DAD secondary structures and a lower binding free energy (ΔG).
  • Six hotspot residues, including L289, located in AKR1B1's α8 and H2 helices were identified as critical for the interface.

Conclusions:

  • The study provides a refined model of the DAD/AKR1B1 interaction.
  • Key residues mediating the complex interface were identified, offering insights into AKR1B1's role in cancer.
  • These findings guide future experimental validation and therapeutic strategies targeting the DAD/AKR1B1 interaction.

Related Concept Videos

Enzyme Inhibition01:30

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
Enzymes02:34

Enzymes

Inside living organisms, enzymes act as catalysts for many biochemical reactions involved in cellular metabolism. The role of enzymes is to reduce the activation energies of biochemical reactions by forming complexes with its substrates. The lowering of activation energies favor an increase in the rates of biochemical reactions.
Enzyme deficiencies can often translate into life-threatening diseases. For example, a genetic abnormality resulting in the deficiency of the enzyme G6PD...
Ligand Binding and Linkage00:49

Ligand Binding and Linkage

Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked.  In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence the...
Allosteric Proteins-ATCase01:19

Allosteric Proteins-ATCase

Binding sites linkages can regulate a protein's function.  For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to  N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...